Alzheimer’s Disease testing on the Randox Evidence Series
What is Alzheimer’s Disease?
Alzheimer’s Disease is a progressive disease and is one of the most common kinds of dementia.
Our brains are made up of billions of tiny nerve cells which connect to each other. However, if you have Alzheimer’s Disease the connections between the cells are lost, which results in the loss of brain tissue and causes nerve cells to die1.
The brain is responsible for sending signals between cells. Those who suffer with Alzheimer’s have less ‘chemical messengers’ in their brain, so the signals are not passed on as well1.
The statistics of those who suffer with dementia is increasingly high and the figure is set to rise in the foreseeable future. Over 850,000 people are living with dementia in the UK. Studies states that one million people in the UK will have dementia in 2025 and this will increase to two million by 2050.2
Symptoms of Alzheimer’s Disease
The symptoms of Alzheimer’s disease are divided into 3 main stages; early symptoms, middle-stage symptoms and later symptoms.
In the early stages, the main symptom of Alzheimer’s disease is memory lapses which can increase anxiety or agitation. In the early stages, it is often mistaken that the person is forgetful and aren’t aware they are suffering with Alzheimer’s. The typical signs are listed below:3
- forget about recent conversations or events
- misplace items
- forget the names of places and objects
- have trouble thinking of the right word
- ask questions repetitively
- show poor judgement
- become less flexible and more hesitant to try new things
As the disease progresses, the symptoms will gradually get worse. Memory problems will get worse which can make it difficult for the person who suffers with the disease to remember names of their loved ones, recent events and even remember birthdays and anniversaries. More symptoms such as the following will develop;3
- increasing confusion and disorientation – for example, getting lost, or wandering and not knowing what time of day it is
- obsessive, repetitive or impulsive behaviour
- delusions or feeling paranoid and suspicious about carers or family members
- problems with speech or language
- disturbed sleep
- changes in mood
- difficulty performing simple tasks and may need additional support e.g. help with eating, getting dressed etc.
In the later stages of Alzheimer’s disease, the symptoms become increasingly severe and patients will need full-time care and assistance. It will be problematic for the individual to do basic everyday tasks such as getting changed, going to the toilet, getting washed and feeding themselves. They could lose their speech, and have difficulty eating and swallowing which can result in severe weight loss.
How Randox can help
Randox want to help. Our Evidence immunoanalyser has revolutionised laboratory screening worldwide with the capability to process 3,960 tests per hour and a sample capacity of 360. We offer the Apolipoprotein E4 (ApoE4) Array for Alzheimer’s genetic risk assessment, which is a research use-only product developed for the Evidence Investigator. The ApoE4 Array measures both total ApoE protein levels and ApoE4 protein levels directly from plasma samples and using a ratio can classify patients as negative or positive for ApoE4. In turn we can then assess their risk for the development of Alzheimer’s disease.
For further information about the Randox Alzheimer’s Array or our Evidence Investigator, please email firstname.lastname@example.org
National STIQ Day
National STIQ day was introduced in 2010 and every year since then the 14th of January has been dedicated to raising awareness for STIQ. The purpose is to emphasize the importance of sexual health and to encourage everyone to get regular health checks.
Sexually Transmissible Infections (STIs) are infections passed from one person to another through unprotected vaginal, oral, or anal sex, or genital contact.
Lack of symptoms
More and more people in the UK are catching STIs and each year the infection rate is rising. According to The World Health Organization (WHO), more than 1 million STIs are acquired every day and the majority of these STIs have no symptoms.1 Therefore you could have an STI and not be aware. 70% of women and 50% of men show no symptoms after contracting Chlamydia which is the most common STI condition in the UK.2
Even though the majority of the time symptoms of STIs aren’t visible, there can be signs of having an STI, including unusual discharge from the vagina, penis or anus, pain when peeing, lumps or skin growth around the genitals, a rash, unusual bleeding, itchiness or blisters around the genitals.3
What to do when you catch an STI
Anyone can catch an STI regardless of what age you are, your sexuality or how many sexual partners you have, as it only takes one sexual encounter to put you at the risk of catching an STI. A shocking fact from Public Health England shows that a case of chlamydia or gonorrhea is diagnosed in a young person every 4 minutes in England, and over 144,000 diagnoses of these sexually transmitted infections are seen in people aged 15 to 24 in 2017. 4
It is extremely important to get routinely tested. The earlier the diagnosis is made and treated the less chance of having long-term effects including infertility.
Randox Biosciences 10-plex STI test
Randox Biosciences would like to take the opportunity to support STIQ day by offering our CE marked 10-plex STI test, a cost-effective solution for accurate STI testing. This test detects the following 10 infections simultaneously from a single patient urine sample.
- Neisseria gonorrhoea (NG)
- Mycoplasma genitalium (MG)
- Ureaplasma urealyticum (UU)
- Chlamydia trachomatis (CT)
- Trichomonas vaginalis (TV)
- Haemophilus ducreyi (HD)
- Mycoplasma hominis (MH)
- Treponema pallidum (TP)
- Herpes simplex virus 1 (HSV-1)
- Herpes simplex virus 2 (HSV-2)
Does your laboratory or clinic carry out STI testing? Our molecular analyser, the Bosch Vivalytic, powered by our award winning Biochip Array Technology, could be the diagnostic solution.
For more information about our STI Arrays or Vivalytic email: email@example.com
The Randox Clinical Laboratories Services (RCLS) team strives to meet the time sensitive, custom-made requirements of research and clinical projects. Accordingly, RCLS is also able to provide support and guidance. They specialise in biomarker and multiplex testing which provide full laboratory services to aid project aims and timelines whilst saving time and money. Currently, there are four laboratories across the UK located in Liverpool, London, Holywood and the Randox Science Park in Antrim.
In 2017 approximately 422,000 diagnoses of STIs were made in England1 and over one million STIs are acquired every day 2.
Sexually transmitted infections (STIs) are a viral or bacterial infection passed from one person to another through unprotected sexual contact.3 Most STIs are curable however, it takes time for the symptoms to appear or show up in tests. Others have no cure, such as HIV, but can be treated to prevent the disease getting worse. Common symptoms of STIs include vaginal discharge, urethral discharge or burning in men, genital ulcers, and abdominal pain 2 although, a person can have an STI without having obvious symptoms of disease.
Randox Clinical Laboratory Services offers a multiplex sexually transmitted infection array allowing you to outsource sample STI testing. It includes common STIs such as Chlamydia, Gonorrhoea, Syphilis, Herpes Simplex I, Herpes Simplex II. The full Multiplex Array can be seen below.
The simultaneous detection is made possible by our award-winning and innovative Biochip Array Technology which utilises multiplex testing methodology in a rapid and accurate format. The type of sample which is sent to our RCLS lab is determined by the visibility of the symptoms. Non-visible symptoms will require a urine sample whereas visible symptoms will require a swab sample.
There are many benefits to outsourcing your STI samples with RCLS, which include the following:
- ISO17025 Accredited Laboratories
- Excellent precision, specificity, sensitivity and accuracy for diagnosis
- Reduced risk of false reporting and a reduced number of unnecessary tests
- Smaller sample volumes are required therefore enabling faster throughput and rapid patient diagnosis
STI Multiplex Array:
- Chlamydia trachomatis
- Neisseria gonorrhoea
- Herpes simplex 1
- Herpes simplex 2
- Treponema pallidum
- Mycoplasma hominis
- Ureaplasma urealticum
- Mycoplasma genitalium
- Haemophilius ducreyi
- Trichomonas vaginalis
If you would like more information on RCLS or our STI testing please contact firstname.lastname@example.org
The Evidence Investigator analyser is based on the award-winning Biochip Array Technology (BAT). Biochip Array Technology is a multi-analyte testing platform allowing the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.
The Evidence Investigator is a semi-automated benchtop analyser which is tailored for the areas of research, forensic, clinical, molecular and veterinary testing. The key feature is the fast turn-around time the Evidence Investigator can process up to 44 results from a single sample, with a maximum throughput of up to 2375 tests per hour. The Evidence Investigator saves time because it will carry out multiplex testing which will allow multiple tests to be carried out from a single patient sample which in return will save time and resources. The machine is more suitable for medium throughput laboratories.
The technology offers a wide-ranging and diverse test menu which will benefit the research areas immunology, metabolic, Sport & Exercise, oncology and cardiovascular. Randox Research provides the Evidence Investigator to the five research areas to help their research become more efficient, cost effective and accurate.
Randox works extremely hard with their research and development, over 16% of turnover is reinvested in R&D. The current collaboration Randox works along with are Royal Victoria Hospital, Queen’s University Belfast and Cambridge University.
Randox Biosciences are dedicated to assisting research projects to completion and will make available the technology to ensure the universities receive highly accurate results for their research. Randox creates their products in-house therefore provides the flexibility of the research project. Randox can provide the university a full range of arrays, biomarkers and analysers to meet their requirements of the research.
Within Cardiovascular Research, Randox offer a comprehensive menu of cytokines. The combination of highly specific antibodies and advanced chemistries enables cytokines, cytokine receptors and growth factors to be detected simultaneously in a single sample, providing valuable information relating to each cytokine under test and possible associations between cytokines in each sample which will benefit the research. Randox offer excellent tools for universities and hospitals researchers such as routine and novel assays and can provide research analysers such as the Evidence Investigator which is suitable for medium sized laboratory.
Oncology Research has 20 biomarkers that can be custom-made to be used on the Biochip. Randox Biosciences offers a wide and extensive test menu to researchers to enable the specific product tailored to meet their clinical trail requirements.
Metabolic & Nutrition Research is another area Randox offers a wide-ranging range of tests specifically directed to Metabolic and Nutrition Research. Randox offers reagents and arrays on the award-winning Biochip Array Technology.
For more information on our Research areas and the tests that we can provide, contact us at – Info@RandoxBiosciences.com
Biochip Array Technology
In 1992, Randox invested £180 million to create and introduce Biochip Array Technology (BAT) which converted laboratory testing. Randox came up with the innovation by recognising the major problem with traditional diagnosis. Within traditional diagnosis several tests are typically required which involves multiple blood draws from the patient, many visits to the hospital, increased reagent volume and increased time to diagnosis. Biochip Array Technology allows for the simultaneous quantitative or qualitative detection of a wide range of analytes from one single sample. Therefore, it is faster, cost saving and more effective leading to better clinical decisions. Today the technology (BAT) is used in countless laboratories worldwide and a range of three biochip analysers are now offered.
The main basis of the Biochip Array Technology
- 9x9mm biochip which acts as a solid phase reaction vessel.
- Each of the biochips are pre-coated with an array of discrete test regions (DTRs)
- One biochip per sample used to generate multiple results.
- Randox Biochips hold up to 49 tests.
- Based on chemiluminescent signal emitting light, without heat which results a chemical reaction.
The key features and benefits of the Biochip Array Technology
Highly accurate testing
- The biochip array technology provides high standard of accurate test results with CV’s <10%
- Multiplex analysis minimises analytical variation between the tests.
- Increased patient information available through testing multiple markers
- Patients receive their results quicker compared to the traditional diagnosis.
Reduced sample volume
- Reduced sample required therefore patients feel more at ease.
Wide test menu
- Wide test menu provides a variety for clients and allows flexibility.
- Multiple samples can be used on BAT which include the following; serum, plasma, whole blood, urine and many others which allows for flexibility in their testing
– The process reduces the amount of time spent on individual tests and associated laboratory costs
Biochip testing platforms
The Evidence Evolution is fully automated random-access biochip testing platform. The machine allows any test to perform at any time as it is a highly versatile analyser which can operate any workflow. It can receive 2640 tests per hour which means the machine has a fast turnaround time. As well as this, it allows multiple tests to be performed from a single sample which reduces time and resources spent on individual tests. The Evidence Evolution can be tailored to certain laboratory needs and have features including automatic start-up and shut down, relaxed testing capability and traceability of biochips. The equipment overall is made to be easy for the client to use as it includes customisable user settings and easy to follow result screens giving them the fast and accurate operations they would prefer.
The Evidence Analyser is the protein Biochip Array technology. Like the Evidence Evolution it is fully automated which is suitable for busy laboratories, hospitals, forensic and clinical toxicology. The machine is floor standing and can receive up to 3690 per hour. The machine has features such as easy to follow software and customisable user settings which gives laboratories the opportunity to receive fast and accurate results.
The Evidence Investigator is often used for research, clinical, forensic, molecular and veterinary testing. The machine is semi-automated and can combine immunoassay and molecular diagnostics on a single platform with protein and DNA biochips. This machine also has a quick turnaround time with the ability to achieve 2376 tests per hour with 44 analytes screened per biochip. The evidence investigator provides more tests on the test menu which allows variety.
The final platform is the Evidence MultiSTAT. The Evidence MultiSTAT is a fully-automated analyser which provides quality results. It is a simple and easy to use analyser which requires minimal training with only three steps to complete the process. The machine can provide multiplex testing yields up to 46 results in under ten minutes. It is ease-of-use for non-laboratory staff and provides full traceability of user action with password controlled software.
Southeast Asia’s economy is booming, increasing every year by 5% and is expected to continue to grow due to an expanding consumer market, a young workforce and increasing regional cooperation. However, these are not the only markets experiencing the boom. The region’s illicit markets are also enjoying a surge.
Drug labs in Southeast Asia are releasing two to six billion methamphetamine tablets a year into the black market, which NPR reports is more tablets than cups of coffee sold by Starbucks. A lot of these tablets go into China and Thailand, with more finding their way to Bangladesh each year. As a result, seizures of meth tablets have gone up in the last 10 years in Bangladesh by 80,000 percent.
China not only receives large quantities of drugs to be sold on the streets, it also produces them. As China is soon set to become the world’s largest economy it now has plenty of people who can afford the products. So the drug lords and dealers are moving towards this market. This means that drug cartels don’t have to go further afield to sell their drugs.
China’s “One Belt One Road” plan has also enabled the easier trafficking of drugs. The plan is to connect the world with highways, ports, airports, and train lines to allow commerce to move to and from China easily. This connected infrastructure has made it easier for smugglers to move their products from A to B.
Randox Toxicology’s DoA ULTRA panel detects 20 targeted drugs including methamphetamine and amphetamine. Utilising our patented Biochip Array Technology, DoA ULTRA offers the most comprehensive drugs of abuse screen across multiple forensic matrices and provides the largest cross-reactivity profile of over 240 analytes from a single sample.
|LOD: 10 ng/mL||PMMA HCI||291|
World Alzheimer’s Month
World Alzheimer’s Month is a global campaign to raise awareness and highlight the challenge that surrounds the disease, hosted by the Alzheimer’s disease International (ADI) every September. During this month World Alzheimer’s Day also takes place, 21 September each year.
47 million people are living with Alzheimer’s worldwide, costing 604 billion USD per year. This number is expected to rise to 76 million people with the disease by 2030.1 The FDA have not approved a medication for the treatment of Alzheimer’s disease since 2003. More than 400 clinical trials are currently looking at new treatments for Alzheimer’s disease (AD) and many of them are actively recruiting. Many still regard the amyloid hypothesis as a key explanation for Alzheimers disease development and progression.2
Alzheimer’s disease is not necessarily inherited as a single-gene mutation as the inheritance pattern is incredibly complex. Unlike familial Alzheimer’s disease, a multi-gene form usually affects those aged 65 and older. The gene with the greatest known effect on the risk of developing late-onset Alzheimer’s disease is called apolipoprotein E (APOE). It is found on chromosome 19 and the APOE protein plays a role in handling fats in the body, including cholesterol. 3
ApoE plays a key role in lipid metabolism and the scientific and medical community recognise it as one of the most powerful genetic risk factors for dementia and other neurodegenerative diseases. It has become one of the most widely studied gene variants in Alzheimer’s disease and constitutes a major consideration for preventive medicine.
ApoE exists in three common isoforms (ApoE2, ApoE3 and ApoE4) which are coded by three co-dominant alleles (e2, e3, e4). As such, six common ApoE phenotypes exist within the general population: E2/E2, E3/E3, E4/E4 (homozygous) and E2/E3, E2/E4, E3/E4 (heterozygous). Medical professionals recognise the presence of the ApoE4 isoform as a major genetic risk factor for development of Alzheimer’s disease. Therefore, the availability of analytical methods for rapid and reliable ApoE4 classification is advantageous.
The Apolipoprotein E4 (ApoE4) Array is a research use only product developed for the Evidence Investigator. The ApoE4 Array measures both total ApoE protein levels and ApoE4 protein levels directly from plasma samples and using a ratio can classify patients as negative or positive for ApoE4. In turn we can then assess their risk for the development of Alzheimer’s disease.
2-plex Biochip Array
- Pan ApoE
An individual’s ApoE status has been shown to affect pre-symptomatic risk, diagnosis, prognosis, and treatment response for a variety of diseases, in particular Alzheimer’s disease. The ApoE4 Array can rapidly and accurately detect an individual’s ApoE4 status directly from a plasma sample. In combination with medical and family history, medication and lifestyle, this can deliver valuable information for personalised medicine approaches.
The 2-plex diagnostic Alzheimer’s test has the utility to detect the likelihood of a person’s chance of developing the disease to assist in the research and development of a potential drug to combat or slow down the process of Alzheimer’s.
For further information about the Randox Alzheimer’s Array, please email email@example.com
Continuing our theme of Biotin (Vitamin B7) this month, we turn our attention to its role in diagnostic testing.
With as many as 20% of people taking biotin-containing supplements, including high profile celebrities such as Kylie Jenner, Kim Kardashian and Vanessa Hudgens, it is important to know the effects it can have on particular blood tests, should you visit your GP or local hospital.
Whilst there are various diagnostic health tests out there, including fertility hormone tests, prostate tests, and tests for troponin – a marker released into the blood during a heart attack – that are known to be affected by elevated levels of biotin, there are other tests available, including those provided by Randox, that are not impacted.
The reason that so many non-Randox tests are impacted by biotin is that biotin is widely used throughout the biotechnology industry in the development of diagnostic tests.
ELISA tests in particular (tests that measure the reaction of antibodies to identify a substance) often make use of antibodies labelled with biotin, to detect toxins or other foreign substances within the body.
In most instances, the biotin will bind with high affinity to a protein called streptavidin. This affinity of streptavidin for biotin is the strongest non-covalent biological interaction known, and is therefore particularly useful in binding antibodies within diagnostic tests.
But with more and more people exceeding the recommended daily dosage for biotin (30 micrograms) by taking up to 10,000 micrograms of biotin in supplements marketed for beauty reasons, many diagnostic tests are being measured inaccurately. Excess biotin in the blood can block the binding of biotin-labelled antibodies to streptavidin within the tests, and the substance being tested won’t be measured accurately.
Laboratory professionals have known about this potential problem for some time. In late November 2017, the FDA (Food and Drug Administration) published a safety notice to make the public and healthcare practitioners more aware that biotin can “significantly interfere with certain lab tests and cause incorrect test results.”
The FDA even reported on one particular case in which a patient died following falsely low troponin (marker of a heart attack) results when the troponin test used was known to have biotin interference. Biotin supplements masked the true diagnosis of a heart attack.
Many patients taking biotin supplements have also been misdiagnosed with a condition called Graves’ disease, an autoimmune condition characterised by an overactive thyroid. In these cases, biotin supplementation led to falsely low levels of thyroid stimulating hormones, and falsely high levels of other thyroid hormones. This particular profile of hormones led to a Graves’ disease diagnosis, in spite of a lack of symptoms, which in Graves’ disease would usually include muscle weakness, a quickened heartbeat, sleeping problems, diarrhoea, weight loss and poor tolerance of heat.
In pregnant women, tests that are impacted by biotin interference may produce falsely low levels of beta HCG, more commonly known as the ‘pregnancy hormone’ as it released by the placenta after conception. With low levels of beta HCG, and therefore no confirmation of pregnancy, pregnant women could be exposed to X-rays and CT scans that may harm the developing foetus.
So, what can be done? Suggestions have been made that patients taking biotin supplements should be made to wait before any diagnostic testing is conducted, so that the biotin clears from their system.
But this “Wait and Watch” approach certainly would not work in emergencies. In the case of a heart attack, testing must be conducted as soon as possible to allow for diagnosis, immediate medical intervention and follow-up testing.
At Randox, we are convinced that the risk of analytic interference by biotin supplementation is a serious problem that needs to be more widely recognised and promptly addressed.
In the GP setting, general practitioners must ask their patients if they are taking any biotin supplements and inform the testing laboratory if interference from biotin is a possibility. They should also consider that lab results not matching with a patient’s signs and symptoms may be caused by biotin interference.
In the acute care setting however, it is imperative that biotin technology is not used in diagnostic testing to protect patients from misdiagnosis and subsequently, further health problems.
This is why Randox’s patented Biochip Array Technology does not use biotin technology in its development. This revolutionary methodology, free from Biotin-Streptavidin is not impacted by elevated levels of biotin from biotin supplementation in the same way as Biotin-Streptavidin tests.
So if you have been taking biotin supplements for hair or nail growth, to ease symptoms associated with Multiple Sclerosis, for epilepsy or for a range of other health conditions, and your diagnostic testing has been conducted using Randox Biochip Array Technology, you can rest assured of true, accurate, and reliable results.
Randox Biochip Array Technology is interference-proof.
For further information on the Randox Biochip, visit https://www.randox.com/multiplex-testing/
For any additional questions, please contact Randox PR by email: firstname.lastname@example.org or by phoning 028 9442 2413
Randox Biosciences is a world-leading primary manufacturer of high quality monoclonal and polyclonal antibodies, antibody fragments and human recombinant proteins. Our team of scientists possess unrivalled expertise which enables us to provide you with a comprehensive suite of products and services dedicated to advancing biopharmaceutical research and diagnostics.
Randox Biosciences offers an extensive portfolio of over 900 products for a multitude of R&D applications including more than 500 monoclonal and polyclonal antibodies and over 140 human recombinant proteins as well as antibody fragments, buffers & diluents and plasma.
- Biochemical markers: Biochemical messengers, fatty acid binding proteins and products with applications in the following therapeutic areas; cardiovascular/cerebrovascular and metabolic/Nutrition
- Drugs of abuse: Alcohol, anti-depressants, barbituates, hallucinogens, opiates, stimulants
- Drug Residues: antimicrobial drugs, growth promoters, mycotoxins
- Biochemical markers: Biochemical messengers, fatty acid binding proteins and products with applications in the following therapeutic areas; Immunology, Oncology, Cardiovascular/Cerebrovascular and Metabolic/Nutrition
- Drugs of abuse: Alcohol, Analgesics, Anti‑depressants, Barbituates, Benzodiazepines, Hallucinogens, Opiates, Sedatives, Stimulants, Synthetic Drugs, Therapeutic drugs
- Drug Residues: Anti-inflammatory Drugs, Antimicrobial Drugs, Anti-Parasitic Drugs, Growth Promoters, Mycotoxins
Recombinant Antibody Fragments
- Single chain variable fragment (scFvs)
- Single domain antibodies (sdAbs)
Frozen Human Plasma
- Available in three formats (Male, Female and Mixed Gender)
- Highly screened for; HIV, Hepatitis B+C, HTLV I + II, Syphilis, CMV and Procleix WNV
Human Recombinant Proteins (E.Coli & Mammalian)
- Adhesion Molecules
- Tumour markers
Buffers & Diluents
- Complementary range available
Key Features & Benefits
- All products manufactured at our ISO 13485 accredited UK manufacturing plant
- Product range of over 900 products
- 30 years’ experience in raw material manufacture and assay development
- Many unique and novel products including designer drugs, Mycotoxins and oncology markers
- As our host animals are sheep, our antibodies have higher sensitivity and specificity
- Excellent reproducibility between lot numbers
- Products reflect the components used in-house in the production of Randox diagnostic products and research programs
- Highly experienced in developing difficult targets (i.e. small molecules and novel biomarkers)
- Full customisation service available
- A range of pack sizes available including bulk quantities for commercial development
- Products can be used in a multitude
Custom Development Services
To meet your precise requirements, Randox Biosciences offer customised antibody generation services to the pharmaceutical and biotechnology industry. Our custom development service, which encompasses antibodies and human recombinant proteins has achieved tremendous success within the biopharmaceutical and diagnostic industries. Key components of our custom service are our range of monoclonal antibodies as well as our recombinant antibody fragments (sdAbs, scFvs, fAbs).
Our customisation service has proven incredibly successful in the research and development industries allowing access our expertise to obtain the antibody and protein most relevant to your line of work. With over 300 highly trained research scientists and over 30 years’ experience in commercial assay development, Randox Biosciences can also provide a tailor-made assay development service to meet your specifications in both a timely and cost-effective manner.
For more information contact: info@Randoxbiosciences.com
World-leading medical diagnostics manufacturer Randox Laboratories is this week showcasing advancements in biotechnology at the world’s largest diagnostics conference, being held in Chicago, Illinois.
The American Association of Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo, known as the leading event for laboratory medicine worldwide, offers Randox the opportunity to showcase their capabilities to more than 20,000 healthcare professionals and decision makers from around the globe.
“Our pioneering diagnostic technologies are leading the way in innovation and have real potential to transform healthcare around the world,” said Randox Managing Director, Dr Peter FitzGerald.
“At AACC we will be hosting demonstrations of a wide range of our intuitive multiplex analysers, including the revolutionary Randox Evidence Evolution, the world’s first fully automated random-access testing platform, capable of delivering 2640 results in one hour, with the first delivered in just 37 minutes.”
The unique and unrivalled capabilities of the Randox Evidence Evolution are made possible thanks to Randox’s patented Biochip Array Technology, which can currently run 49 different tests simultaneously – ensuring an accurate and reliable diagnosis as fast as possible.
Launching at this year’s AACC event are a number of exciting new tests on the Randox Biochip, the result of a £280 million investment in research and development. Including but not exclusive to a diagnostic test for the differentiation of hemorrhagic and ischemic strokes, an algorithm capable of generating a patient’s Type 1 Diabetes Genetic Risk Score, and a test to diagnose Acute Kidney Injury (AKI) in the participants of pharmaceutical drug trials, these new tests all share the common goal of much earlier and effective diagnosis, to greatly improve healthcare outcomes and reduce the burden on healthcare services.
Dr. FitzGerald continued;
“We remain committed to developing new health diagnostic technologies for a range of the world’s most pressing health issues in need of the most urgent address, and to expanding the business in our key markets, such as the US.
“Our very significant investment in research and development means that we have more new tests in development than any other healthcare company in the world and are able each year to bring a wealth of exciting new technologies to the American market.
“We look forward to showcasing our latest innovations at this year’s AACC conference, and how they can be utilised to save, improve and extend lives through the earliest possible diagnosis. Randox technology can truly revolutionise the future of healthcare.”
AACC runs from the 29th July – 2nd August at McCormick Place in Chicago, Illinois. Randox can be found at booth #3624.
For further information visit aacc.randox.com